|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2001-5-14
|
|
pubmed:abstractText |
In vitro low concentrations of hydroxyurea eliminate double-minute chromosomes (dmins) containing amplified drug-resistance genes and oncogenes from cancer cells. This clinical trial investigated whether a noncytotoxic dose of oral hydroxyurea could reduce the number of dmins in cancer cells in patients with advanced ovarian carcinomas.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1171-80
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11350881-Administration, Oral,
pubmed-meshheading:11350881-Adult,
pubmed-meshheading:11350881-Aged,
pubmed-meshheading:11350881-Aged, 80 and over,
pubmed-meshheading:11350881-Antineoplastic Agents,
pubmed-meshheading:11350881-Chromosomes, Human, Pair 15,
pubmed-meshheading:11350881-DNA, Neoplasm,
pubmed-meshheading:11350881-Female,
pubmed-meshheading:11350881-Gene Amplification,
pubmed-meshheading:11350881-Humans,
pubmed-meshheading:11350881-Hydroxyurea,
pubmed-meshheading:11350881-Metaphase,
pubmed-meshheading:11350881-Middle Aged,
pubmed-meshheading:11350881-Neoplasm Staging,
pubmed-meshheading:11350881-Ovarian Neoplasms
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas.
|
|
pubmed:affiliation |
Institute for Drug Development-Cancer Therapy and Research Center, San Antonio, Texas 78245-3217, USA. raymond@igr.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
